36116-18-4

Usage

Uses

Used in Pharmaceutical Synthesis:
Cyclopropy(4-hydroxyphenyl)methanone is used as a key intermediate in the synthesis of various pharmaceutical drugs due to its reactivity and ability to form a cyclopropyl ring, which can enhance the potency and selectivity of the resulting compounds.
Used in Organic Chemistry:
As a versatile building block, Cyclopropy(4-hydroxyphenyl)methanone is utilized in organic chemistry for the creation of a wide range of organic compounds, leveraging its unique structural features to achieve specific chemical transformations and reactions.
Used in Agrochemical Production:
Cyclopropy(4-hydroxyphenyl)methanone serves as an intermediate in the production of agrochemicals, contributing to the development of effective and targeted pest control agents.
Used in Fine Chemicals Industry:
Cyclopropy(4-hydroxyphenyl)methanone is also used in the fine chemicals industry, where its unique properties are harnessed to produce specialty chemicals for various applications, including fragrances, dyes, and other high-value products.
Used in Biological Research:
Cyclopropy(4-hydroxyphenyl)methanone is used in biological research as a subject of study for its potential anti-inflammatory and antioxidant properties, with the aim of discovering new therapeutic agents or understanding its biological mechanisms of action.
While the specific applications and industries for Cyclopropy(4-hydroxyphenyl)methanone are outlined above, it is important to note that ongoing research is essential to fully realize the compound's potential and to safely and effectively integrate it into various fields.

Upstream product

• 7150-55-2 γ-chloro-4-hydroxybutyrophenone 
• 6746-94-7 Cyclopropylacetylene 
• 106-51-4 p-benzoquinone 
• 4023-34-1 cyclopropanecarboxylic acid chloride 
• 108-95-2 phenol 
• 100-66-3 methoxybenzene 
• 113425-33-5 4-hydroxy-1-(4-hydroxyphenyl)-butan-1-one 
• 873-75-6 4-bromobenzenemethanol 
• 1759-53-1 cyclopropanecarboxylic acid 
• 7152-03-6 p-methoxyphenyl cyclopropyl ketone 
• 3874-54-2 4-(4-fluorophenyl)-4-oxo-n-butyl chloride 

Downstream Products

• 36116-10-6 {4-[3-(4-Cyclopropanecarbonyl-phenoxy)-2-hydroxy-propoxy]-phenyl}-cyclopropyl-methanone 
• 315674-93-2 cyclopropyl-{4-[3-(1-trityl-1H-imidazol-4-yl)-propoxy]-phenyl}-methanone 
• 1539286-75-3 C₁₁H₉F₃O₄S 
• 97732-34-8 4-cyclopropylmethylphenol 

Relevant academic research and scientific papers

In situ cyclopropanation: A rapid one-pot method for the synthesis of resin bound cyclopropyl phenyl methanones as combinatorial scaffolds

An efficient, high yielding one-pot synthesis of 4-substituted cyclopropyl phenyl methanones bound to RAM and WANG resins has been developed. The resin bound cyclopropyl phenyl methanone served as a combinatorial scaffold for the generation of structurally diverse alicyclic compounds.

Structural modifications in the distal, regulatory region of histamine H3 receptor antagonists leading to the identification of a potent anti-obesity agent

A series of 4-pyridylpiperazine derivatives with varying regulatory region substituents proved to be potent histamine H3 receptor (H3R) ligands in the nanomolar concentration range. The most influential modification that affected the affinity toward the H3R appeared by introducing electron-withdrawing moieties into the distal aromatic ring. In order to finally discuss the influence of the characteristic 4-pyridylpiperazine moiety on H3R affinity, two Ciproxifan analogues 2 and 3 with a slight modification in their basic part were obtained. The replacement of piperazine in 3 with piperidine in compound 2, led to slightly reduced affinity towards the H3R (Ki = 3.17 and 7.70 nM, respectively). In fact, 3 showed the highest antagonistic properties among all compounds in this series, hence affirming our previous assumptions, that the 4-pyridylpiperazine moiety is the key element for suitable interaction with the human histamine H3 receptor. While its structural replacement to piperidine is also tolerated for H3R binding, the heteroaromatic 4-pyridyl moiety seems to be essential for proper ligand-receptor interaction. The putative protein-ligand interactions responsible for their high affinity were demonstrated using molecular modeling techniques. Furthermore, selectivity, intrinsic activity at the H3R, as well as drug-like properties of ligands were evaluated using in vitro methods. Moreover, pharmacological in vivo test results of compound 9 (structural analogue of Abbott's A-331440) clearly indicate that it may affect the amount of calories consumed, thus act as an anorectic compound.

Visible Light-Mediated [2 + 2] Cycloaddition Reactions of 1,4-Quinones and Terminal Alkynes

A single-step synthesis of 4-hydroxy-functionalized bi-aryl and aryl/alkyl ketones via oxidative coupling of terminal alkynes with benzoquinones is reported. Furthermore, with naphthoquinones, owing to the cross-resonance of carbonyl with the aromatic ring, alkene-alkyne cycloaddition is more favored to give four-membered carbocyclic adducts, thereby precluding the requirement of preactivated alkynes.

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula:wherein B is a nucleobase selected from the groups (a) to (d):and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER

The invention provides compounds of formula (I), wherein: R1 is OR11, or NR5R5'; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(=O)R6, O(C=O)R6 or O(C=O)OR6; R5′ is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula:(I) wherein B is a nucleobase selected from the groups (a) to (d) and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula (I) wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

N-HETERO-RING-SUBSTITUTED AMIDE DERIVATIVE

Compounds are provided having an excellent hypoglycemic effect and β cell- or pancreas-preserving effects or pharmaceutically acceptable salts thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause hyperglycemia due to abnormal glucose metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.

Synthesis and biochemical evaluation of a series of trifluoromethanesulfonate derivatives of 4 hydroxyphenyl ketones - Probes of the active site of type 1 and 3 of the 17β-hydroxysteroid dehydrogenase family of enzymes

In an effort to aid the design of 'dual-inhibitors' of types 1 and 3 of the 17β-hydroxysteroid dehydrogenase (17β-HSD), we report the synthesis, biochemical evaluation and rationalisation of the inhibitory activity of trifluoromethanesulfonate derivatives of 4-hydroxyphenyl ketone-based compounds which were found to be weak inhibitors of types 1 and 3.